ID TT2609-A02 AC CVCL_A594 DR DSMZ; ACC-859 DR DSMZCellDive; ACC-859 DR Wikidata; Q54973222 RX PubMed=11716037; CC Population: Caucasian. CC Doubling time: 68 hours (PubMed=11716037); ~100 hours (DSMZ=ACC-859). CC Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046. ST Source(s): DSMZ=ACC-859 ST Amelogenin: X,Y ST CSF1PO: 12 ST D13S317: 11 ST D16S539: 9,11 ST D18S51: 14 ST D19S433: 13,15 ST D21S11: 28,30 ST D2S1338: 19,25 ST D3S1358: 16 ST D5S818: 12 ST D7S820: 8,10 ST D8S1179: 12,13 ST FGA: 22,25 ST Penta D: 12,14 ST Penta E: 5 ST TH01: 8,9.3 ST TPOX: 8,12 ST vWA: 17,18 DI NCIt; C8054; Thyroid gland follicular carcinoma DI ORDO; Orphanet_146; Differentiated thyroid carcinoma OX NCBI_TaxID=9606; ! Homo sapiens (Human) OI CVCL_A595 ! TT2609-B02 OI CVCL_2218 ! TT2609-C02 SX Male AG 57Y CA Cancer cell line DT Created: 06-06-12; Last updated: 02-05-24; Version: 16 // RX PubMed=11716037; DOI=10.1089/105072501753210966; RA Geldof, Albert A. RA Versteegh, Richard T. RA van Mourik, Johan C. RA Rooimans, Martin A. RA Arwert, Fre RA Hermsen, Mario A.J.A. RA Schadee-Eestermans, Inge L. RA van Dongen, Guus A.M.S. RA van der Valk, Paul RA van der Poest Clement, Evert H. RA Lips, Paul RA Teule, Gerrit J.J. RT "Clonally related but phenotypically divergent human cancer cell lines RT derived from a single follicular thyroid cancer recurrence (TT2609)."; RL Thyroid 11:909-917(2001). //